Technical Innovations & Patient Support in Radiation Oncology (Dec 2021)

Thyroid-optimized and thyroid-sparing radiotherapy in oral cavity and oropharyngeal carcinoma: A dosimetric study

  • Anna K. Wu,
  • Nicholas J. Damico,
  • Erin Healy,
  • Michael Z. Kharouta,
  • Ghazal Khandel,
  • Alok Deshane,
  • Jennifer Sipos,
  • Jacob Eckstein,
  • Wesley Zoller,
  • Ashlee Ewing,
  • Stella Ling,
  • Jessica Wobb,
  • Darrion Mitchell,
  • John Grecula,
  • Sachin Jhawar,
  • Eric Miller,
  • Mauricio Gamez,
  • Virginia Diavolitsis,
  • Dukagjin Blakaj,
  • Aashish D. Bhatt

Journal volume & issue
Vol. 20
pp. 28 – 34

Abstract

Read online

Background: Radiation-induced hypothyroidism is a common toxicity of head and neck radiation. Our re-planning study aimed to reduce thyroid dose while maintaining target coverage with IMRT. Methods: We retrospectively identified patients with oral-cavity (n = 5) and oropharyngeal cancer (n = 5). Treatment plans were re-optimized with 45 Gy thyroid mean dose constraint, then we cropped the thyroid out of PTVs and further reduced thyroid dose. Target coverage was delivering 100% dose to ≥ 93% of PTV and 95% of dose to > 99% of PTV. Results: Originally, average mean dose to thyroid was 5580 cGy. In model I, this dropped to 4325 cGy (p < 0.0001). In model II, average mean dose was reduced to 3154 cGy (p < 0.0001). For PTV low and PTV int, all had acceptable target coverage. Conclusion: In patients with oral-cavity and oropharyngeal cancers, mean dose could be significantly reduced using a thyroid-optimized or thyroid-sparing IMRT technique with adequate coverage.

Keywords